Cetuximab

Identification

Name
Cetuximab
Accession Number
DB00002 / PQX0D8J21J
Groups
Erbitux
Description

Cetuximab is an epidermal boom element receptor binding FAB. Cetuximab consists of the Fv (variable; antigen-binding) areas of the 225 murine EGFr monoclonal antibody precise for the N-terminal part of human EGFr with human IgG1 heavy and kappa mild chain constant (framework) areas. Cetuximab is advertised under the logo Erbitux® by using Eli Lilly and corporation. within the u.s., a routine of cetuximab prices about $30,790 for an 8-week direction.

Pharmacology

Pharmacodynamics

Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.

Indication

Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.

Action

Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.